Impact of pharmacist-led antibiotic stewardship program in a PICU of low/middle-income country

Anwarul Haque,1 Kashif Hussain,2 Romesa Ibrahim,1 Qalab Abbas,1 Shah Ali Ahmed,1 Humaira Jurair,1 Syed Asad Ali1

INTRODUCTION

The use of antibiotics in paediatric intensive care units (PICU) is very high (ranging from 67% to 97%) due to several reasons including high incidence of community-acquired sepsis, healthcare-associated infections or as a postoperative prophylaxis.1 This high antibiotic use leads to several problems including development of antibiotic resistance, drug toxicity and drug interactions.2 The Infectious Diseases Society of America and Society for Healthcare Epidemiology of America has initiated antibiotic stewardship programme (ASP) for better delivery of antibiotics in hospitalised patients in 2007 and updated in April 2016, was also advocated by other paediatric healthcare agencies.3 The cornerstone for ASP is appropriate selection, dose and duration of antibiotics. The advantages of ASP include decrease in antimicrobial resistance and cost of care.4 Reports published on ASP in intensive care units have demonstrated significant improvement in consumptions of antibiotics.5 There are limited published reports on paediatric ASP especially related to PICU.5 7 We implemented pharmacist-led ASP in our PICU and compared it with the historical data on the usage of antibiotics in terms of days of therapy (DOT) per 1000 patient days as well as cost of therapy (COT).

OBJECTIVE

To assess the effect of implementation of pharmacist-led customised ASP and to compare with historical control on usage of antibiotics as well as COT in our PICU.

METHODS

We conducted a multidisciplinary-team pilot project of pharmacist-led prospective-audit-with-feedback ASP from April to June 2016 in our closed multidisciplinary-cardiothoracic PICU. The team members of ASP were paediatric intensivist, critical care pharmacist (KH) specially trained in ASP and paediatric infectious disease physician. The four main components of this programme were1: selection of appropriate agent, based on the patient characteristics like where the patient came from (community or another hospital/ward), previous antibiotics received in current illness, nature of disease/infection and microbiological details available if any before the PICU admission2 appropriate dose,3 de-escalation/discontinuation (stop or change to narrow spectrum antibiotic based on definitive diagnosis after 48 hours) and4 recommendation regarding interactions or monitoring of therapy. During the morning rounds, pharmacist discussed these four components on each patients. DOT was defined as the number of antibiotics patient received in a day.8 Basic demographic (age, gender) characteristics, Paediatric Risk of Mortality III score for severity assessment, admitting diagnostic categories, indications of antibiotics, details of ASP, COT (only cost of drug unit) and outcome as alive/dead were recorded. The COT was taken from the pharmacy bill. The same data were also collected from January to March before the start of ASP. DOT per 1000 patient’s days for overall antibiotic and specific antibiotics (most commonly used antibiotics in PICU like ceftriaxone, vancomycin, meropenem and colistin, etc) were calculated. Data were entered into SPSS V.20 and appropriate statistical tests were used to compare DOT/1000 patient’s days as well as COT before (from historical control data) and after implementation of ASP.

RESULTS

During ASP period, 127 patients were enrolled and 135 patients were enrolled from historical control for same period. Patients’ characteristics were same for both periods (table 1).
Median age was 26 months (range 1 months–16 years) and male was >60% in both periods. Total DOT was 651 in ASP period and 1937 in the pre-ASP period (P < 0.0001). DOT/1000 patient days was 3447 and 1323 in the pre-ASP and ASP periods, respectively (P < 0.0001). There was a 64% reduction in antibiotics utilisation in ASP period. The appropriate use of empirical antibiotic therapy for culture-negative infection-like symptoms (duration ≤ 2 days) increased from 6% (8/135) to 45% (57/127) (P < 0.0001). The DOT of colistin remained same during both the periods (DOT=115 vs 100, P=0.70). COT decreased from US$22 125 in the pre-ASP period to US$9296 in the ASP period (P<0.0001) with cost reduction of 58%.

Pharmacist interventions during the ASP period were 29 (22.6%) and included: dose adjustment (n=11), selection of antibiotic (n=15), de-escalation (n=5), monitoring and interactions recommendation (n=6). Mortality was 16.2% and 15.7% during the pre-ASP and ASP period, respectively.

DISCUSSIONS
We showed a significant and robust impact of ASP on antibiotic utilisation in our PICU. There was 64% reduction in antibiotics use and 58% cost reduction during this customised ASP. Antibiotics, being the most commonly prescribed medications in critical care setting, are epicentre of antimicrobial resistance. Published ASP reports from adult critical care had demonstrated significant positive impact on utilisation of antibiotics with no associated increase in healthcare-associated infection rates, length of stay or mortality like our report.5 There are two main forms of ASP either prior authorisation/restriction policy or prospective-audit-with-feedback

| Table 1 | Patients’ characteristics and antibiotics data during the pre-ASP and ASP periods |
|------------------|-----------------------------------|------------------|------------------|
| Variable          | ASP−n (%)            | ASP+n (%)        | P value          |
| Median age in months (IQR) | 26 (93)              | 24 (65)          | 0.485            |
| Gender male       | 150 (62.5)           | 86 (63)          |                  |
| PRISM-III         | 5.68 ± 5.14          | 7.4 ± 6.3        |                  |
| **Diagnosis**     |                     |                  |                  |
| Respiratory system diseases | 27 (20)              | 31 (24.4)        | > 0.05           |
| Cardiovascular system diseases | 12 (9)               | 13 (10.2)        |                  |
| Neurological diseases | 25 (18.5)           | 16 (12.6)        |                  |
| Surgical disease  | 58 (43)              | 41 (32.3)        |                  |
| Miscellaneous     | 13 (9.5)             | 26 (20.5)        |                  |
| Empirical         | 57 (42)              | 60 (47.4)        |                  |
| Prophylaxis        | 58 (43)              | 55 (43.2)        |                  |
| Therapeutic       | 20 (15)              | 12 (9.4)         |                  |
| **Intervention**  |                     |                  |                  |
| None              | 29 (22.6)            |                  |                  |
| Dose              | None                 | 11 (8.5)         |                  |
| Choice            | None                 | 15 (11.7)        |                  |
| Duration/stop     | 15 %                 | 6 (4.6)          |                  |
| Monitor/interaction | None               | 6 (4.6)          |                  |
| DOT               | 1937                 | 651              |                  |
| <2 days           | 8 (6)                | 57 (45)          |                  |
| >5 days           | 87 (64)              | 8 (6)            |                  |
| Patient’s days (PtD) | 557                 | 492              |                  |
| DOT/1000 PtD      | 1937/0.557=3477      | 651/0.492=1323   | <0.0001          |
| DOT-vanco         | 346                  | 174              | 0.002            |
| DOT-mero          | 323                  | 154              | 0.001            |
| DOT-cols          | 115                  | 100              | 0.70             |
| DOT-ceftri        | 532                  | 186              | 0.00             |
| Cost in PKR       | 2 212 468            | 929 568          | 0.00             |
| Mortality (%)     | 22 (16.2)            | 20 (15.7)        |                  |

ASP, antibiotic stewardship programme; CVS, cerebrovascular disease; DOT, days of therapy; PKR, Pakistani Rupee; PtD, patient days; PRISM, Paediatric Risk of Mortality.
interventions. We followed the latter approach and found it effective like few other clinical reports.\textsuperscript{9, 10} Stocker \textit{et al} reported from their PICU that there was an improvement on empirical use of antibiotics (<3 days) from 18% to 35%, similarly our empiric antibiotic usage improved from 6% to 45%.\textsuperscript{7} Like previous reports, we also observed that the most common pharmacist interventions were selection and dosing of antibiotics. Pentima \textit{et al} reported that about 61% of ASP intervention was dose related.\textsuperscript{11}

Lee \textit{et al} successfully implemented ASP in intensive care units of a tertiary care paediatric hospital and found 62% cost reduction.\textsuperscript{6} With this customised ASP, we can potentially save about US$51 000 (PKR 5 million) annually which being in a low/middle-income country is very significant. This is only cost saving from drug-unit cost excluding pharmacy charges, nurse’s time and other associated expenses of hospital pharmacy which becomes very relevant from limited human resource perspective.

This is the first report from PICU of a low/middle-income country showing highly successful implementation of quality improvement project with a high potential of cost saving. The limitations include a single centre, private sector hospital project implemented over a limited period of time, so its generalisability has limitation. We did not use defined daily dose as recommended by WHO. It is difficult to use in paediatrics because of weight-based dosing. Furthermore, we were unable to report length of therapy (course) along with DOT.

\textbf{Contributors} AH: conceived the idea, did literature search, designed the study, wrote and proofread the manuscript. KH: did the literature search, collected data, helped writing manuscript and proofread it. RL: data management, entry, analysis, writing manuscript and proofreading. QA: led the ASP, did literature search and summarised it, designed data collection tool, collected data, analysed data, wrote manuscripts, proofread it and is the final guarantor of the manuscript. SAA: data collection, entry, analysis, manuscript writing and proofreading. HI: data gathering, manuscript writing, proof reading. SAA: idea, study design, data collection tool design, manuscript writing and proofreading.

\textbf{Competing interests} None declared.

\textbf{Ethics approval} Ethical Review Committee, Aga Khan University Karachi, Pakistan (4373-ped-erc-16).

\textbf{Provenance and peer review} Not commissioned; externally peer reviewed.

\textbf{Open Access} This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

\textbf{REFERENCES}

1. Abbas Q, Ul Haq A, Kumar R, \textit{et al}. Evaluation of antibiotic use in pediatric intensive care unit of a developing country. \textit{Indian J Crit Care Med} 2016;20:291–4.

2. De Waele JJ, Schouten J, Dimopoulos G. Understanding antibiotic stewardship for the critically ill. \textit{Intensive Care Med} 2016;42:2063–5.

3. Barlam TF, Cosgrove SE, Abbo LM, \textit{et al}. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. \textit{Clin Infect Dis} 2016;62:e51–77.

4. Hyun DY, Hersh AL, Namtu K, \textit{et al}. Antimicrobial stewardship in pediatrics: how every pediatrician can be a steward. \textit{JAMA Pediatr} 2013;167:859–66.

5. Kagi R, Elligsen M, Walker S, \textit{et al}. Impact of antibiotic stewardship in critical care: a systematic review. \textit{J Antimicrob Chemother} 2011;66:1223–30.

6. Lee KR, Bagga B, Arnold SR. Reduction of broad-spectrum antimicrobial use in a tertiary children’s hospital post antimicrobial stewardship program guideline implementation. \textit{Pediatr Crit Care Med} 2016;17:187–93.

7. Stocker M, Ferrao E, Banya W, \textit{et al}. Antibiotic surveillance on a paediatric intensive care unit: easy attainable strategy at low costs and resources. \textit{BMCD pediatr} 2012;12:196.

8. Ibrahim OM, Polk RE. Antimicrobial use metrics and benchmarking to improve stewardship outcomes: methodology, opportunities, and challenges. \textit{Infect Dis Clin North Am} 2014;28:195–214.

9. Newland JG, Stach LM, De Lurgio SA, \textit{et al}. Impact of a prospective-audit-with-feedback antimicrobial stewardship program at a children’s hospital. \textit{J Pediatric Infect Dis Soc} 2012;1:179–86.

10 Willis ZI, Gillon J, Xu M, \textit{et al}. Reducing antimicrobial use in an academic pediatric institution: evaluation of the effectiveness of a prospective audit with real-time feedback. \textit{J Pediatric Infect Dis Soc} 2016;6:339–45.

11. Di Pentima MC, Chan S, Eppes SC, \textit{et al}. Antimicrobial prescription errors in hospitalized children: role of antimicrobial stewardship program in detection and intervention. \textit{Clin Pediatr} 2009;48:505–12.